NCT05045534View on ClinicalTrials.gov

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of TB-840 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

September 14, 2021

Primary Completion Date

August 29, 2022

Study Completion Date

December 30, 2022

Conditions
Healthy Volunteers
Interventions
DRUG

Comparison of TB-840 treatment with Placebo

Single dose or Multiple Dose of TB-840 treatment

Trial Locations (1)

13488

Therasid Bioscience, Seongnam-si

Sponsors
All Listed Sponsors
lead

Therasid Bioscience

INDUSTRY

NCT05045534 - A Study to Investigate the Safety, Tolerability and Pharmacokinetics of TB-840 in Healthy Subjects | Biotech Hunter | Biotech Hunter